Alain is a senior life science executive with over 25 years of experience in biopharmaceutical development, GMP manufacturing, and quality assurance. He began his career after earning a PhD in apoptosis research from the University of Berne, with early roles at Schering-Plough, Roche, where he led the tech transfer of the Avastin manufacturing process from Genentech to Roche in Basel, and Merck-Serono, where he oversaw the commercial manufacturing of various hormones. Subsequently, Alain joined Crucell, where he oversaw process and analytical development, including clinical manufacturing of adenoviral vaccines. Following Crucell’s $2.4B acquisition by Johnson & Johnson, Alain joined GSK as Vice President of New Product Introduction & Technical Life Cycle Management, where he oversaw the late-stage development and commercialization readiness of Mosquirix® and Shingrix®. Since 2015, he has led manufacturing and CMC functions in the cell and gene therapy space at Cell Medica, Agentus Therapeutics, and Gamida Cell. Most recently, he served as CTO of Unicyte and supported the WHO mRNA Technology Transfer Programme through site assessments in low- and middle-income countries.

Elena is a graduate of Comenius University with an MA in Business Administration and is a practicing Fellow of the ACCA. She began her professional career at EY as an auditor before joining Fiserv as the CEESEE Regional Finance Lead, where she also drove major strategic initiatives, including the establishment of a new SSC and BPO transitions for EMEA operations, and the implementation of a full Oracle ERP suite. She also led a number of cross‑border M&A projects for Fiserv and Nexi. Elena later moved to BASF as Regional CFO, where she executed multiple corporate restructuring initiatives, oversaw complex tax audits, and played a key role in the development and valuation of a world‑scale industrial enzyme production facility. Elena has 15+ years of experience in accounting, tax, FP&A, M&A and corporate restructuring, ERP implementations, and corporate operations.

Katarina leads grants and procurement at Sensible Biotechnologies, overseeing non-dilutive financing, public funding programmes and procurement across the company’s research, manufacturing and infrastructure activities. She brings extensive experience in public administration, European funding instruments and the implementation of complex, publicly financed programmes. Before joining Sensible, Katarina worked at the National Implementation and Coordination Authority (NIKA) within the Office of the Government of the Slovak Republic, the central body responsible for coordinating implementation of Slovakia’s Recovery and Resilience Plan. Katarina holds a Ph.D. from Masaryk University in Brno, where her academic work focused on political institutions and parliamentary governance.

Marian is a molecular biologist, biochemist, and biotechnology entrepreneur with more than a decade of hands-on experience in genetic engineering, cellular engineering, and nucleic acid research. He co-founded Sensible Biotechnologies in 2021 and leads the company's scientific strategy, platform technology development, process automation, and research roadmap, driving key innovations in cell-based mRNA biomanufacturing and related R&D.

Marian earned his DPhil in Biochemistry from the University of Oxford, where his research focused on DNA repair and genomic stability in human cells. Prior to his Oxford studies and co-founding Sensible Biotechnologies, he conducted biological research across multiple academic institutions in Europe, including Comenius University in Bratislava, the Vienna BioCenter, and the University of Gothenburg. There, he worked with various prokaryotic, eukaryotic, and animal models for both basic biological research and the screening and evaluation of therapeutic candidates. Marian's work lies at the forefront of scalable synthetic biology technologies, aiming to understand and overcome fundamental bottlenecks in the production of complex RNA therapeutics.

Marian is a molecular biologist, biochemist, and biotechnology entrepreneur with more than a decade of hands-on experience in genetic engineering, cellular engineering, and nucleic acid research. He co-founded Sensible Biotechnologies in 2021 and leads the company's scientific strategy, platform technology development, process automation, and research roadmap, driving key innovations in cell-based mRNA biomanufacturing and related R&D.

Marian earned his DPhil in Biochemistry from the University of Oxford, where his research focused on DNA repair and genomic stability in human cells. Prior to his Oxford studies and co-founding Sensible Biotechnologies, he conducted biological research across multiple academic institutions in Europe, including Comenius University in Bratislava, the Vienna BioCenter, and the University of Gothenburg. There, he worked with various prokaryotic, eukaryotic, and animal models for both basic biological research and the screening and evaluation of therapeutic candidates. Marian's work lies at the forefront of scalable synthetic biology technologies, aiming to understand and overcome fundamental bottlenecks in the production of complex RNA therapeutics.

Maria is a graduate of Comenius University in Bratislava, Faculty of Management, with 20 years of HR leadership experience. She built the HR function for a fast-growing consulting firm and later served as HR Country Manager for AT&T in Slovakia and across Central and Eastern Europe. Her responsibilities spanned HR strategy, compliance, employee services, and support for international management, including M&A activities. She also launched HR operations for a new public sector shared service center. Before joining Sensible, Maria led the Payroll Outsourcing division at a tax and accounting firm, supporting clients with diverse needs.

Miro is a biotechnology entrepreneur and biomedical engineer working at the intersection of synthetic biology, RNA therapeutics and biomanufacturing. He co-founded Sensible Biotechnologies in 2021 and has led the company from its inception through multiple financing rounds, international expansion and the development of strategic partnerships across the global biotechnology ecosystem.

Miro earned a First Class MEng in Biomedical Engineering from Imperial College London and is completing a DPhil in Engineering Science at the University of Oxford, where his research focuses on computational and mathematical modelling of complex synthetic biological systems. He has conducted research at Imperial College London, Caltech and Stanford University and was elected a Pontigny Scholar and Simonian Scholar at St Edmund Hall, Oxford. He also received Imperial College London’s Emerging Alumni Leader Award in 2024. Beyond his operating role, Miro has contributed to biosecurity, health and innovation policy, including advising the Ministry of Health of the Slovak Republic and a member of the Executive Board of the World Health Organization.

Miro is a biotechnology entrepreneur and biomedical engineer working at the intersection of synthetic biology, RNA therapeutics and biomanufacturing. He co-founded Sensible Biotechnologies in 2021 and has led the company from its inception through multiple financing rounds, international expansion and the development of strategic partnerships across the global biotechnology ecosystem.

Miro earned a First Class MEng in Biomedical Engineering from Imperial College London and is completing a DPhil in Engineering Science at the University of Oxford, where his research focuses on computational and mathematical modelling of complex synthetic biological systems. He has conducted research at Imperial College London, Caltech and Stanford University and was elected a Pontigny Scholar and Simonian Scholar at St Edmund Hall, Oxford. He also received Imperial College London’s Emerging Alumni Leader Award in 2024. Beyond his operating role, Miro has contributed to biosecurity, health and innovation policy, including advising the Ministry of Health of the Slovak Republic and a member of the Executive Board of the World Health Organization.